Loading
A phase 1/2 trial of MBS314 Injection in multiple myeloma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. is a phase 1/2 interventional study registered as NCT06232096 by Beijing Mabworks Biotech Co., Ltd., with 154 participants planned, started 2024-02-22 and due to reach its primary completion in 2026-02. Interventions recorded: MBS314 Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Beijing Mabworks Biotech and the tag pipeline.
Shares Beijing Mabworks Biotech and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/